Literature DB >> 6231253

Distinction between Burkitt lymphoma subgroups by monoclonal antibodies: relationships between antigen expression and type of chromosomal translocation.

B Ehlin-Henriksson, G Klein.   

Abstract

Twenty-six lines derived from 22 Burkitt lymphoma patients were examined for cytoplasmic vs. surface immunoglobulin and the expression of the monoclonal-antibody-detected BLA, CALLA and LB-I antigens. Six of the lines carried the variant translocations 8;2 or 8;22 (three each), 17 lines had the typical 8;14 translocation, I was translocation-negative (BJAB) and 2 were not examined cytogenetically. Depending on their immunoglobulin and surface marker expression, the BL lines could be subdivided into several subgroups. There was a strong inverse correlation between the expression of the CALLA and the LB-I marker. All BLA-lines were CALLA-, whereas the CALLA+ lines could be either BLA- or BLA+. All six variant translocations belonged to the CALLA-BLA-LBI+ category. Only one set of three lines, derived from the patient with the 8;14 translocation, belonged to the same subgroup. This suggests that the typical vs. the variant translocation freezes the BL cell at a different stage of differentiation. The variant translocation-carrying subtypes represent probably a somewhat more advanced stage of differentiation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6231253     DOI: 10.1002/ijc.2910330407

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt's lymphoma line rael.

Authors:  M G Masucci; B Contreras-Salazar; E Ragnar; K Falk; J Minarovits; I Ernberg; G Klein
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

2.  Distribution of the Burkitt's lymphoma-associated antigen (BLA) in normal human tissue and malignant lymphoma as defined by immunohistological staining with monoclonal antibody 38.13.

Authors:  G Pallesen; J Zeuthen
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

3.  A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes.

Authors:  S Paulie; B Ehlin-Henriksson; H Mellstedt; H Koho; H Ben-Aissa; P Perlmann
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

4.  Immunopathology of non-Hodgkin lymphomas.

Authors:  H Huber; C Gattringer; W Knapp; H Stein
Journal:  Klin Wochenschr       Date:  1984-11-02

5.  Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells.

Authors:  M Rowe; D T Rowe; C D Gregory; L S Young; P J Farrell; H Rupani; A B Rickinson
Journal:  EMBO J       Date:  1987-09       Impact factor: 11.598

6.  Concomitant Inhibition of IRE1α/XBP1 Axis of UPR and PARP: A Promising Therapeutic Approach against c-Myc and Gammaherpesvirus-Driven B-Cell Lymphomas.

Authors:  Rossella Benedetti; Andrea Arena; Maria Anele Romeo; Maria Saveria Gilardini Montani; Roberta Gonnella; Roberta Santarelli; Pankaj Trivedi; Mara Cirone
Journal:  Int J Mol Sci       Date:  2022-08-14       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.